MedTrace Logo

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

NCT05203237 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-02-17

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and otherwise healthy adults who have an increased body mass index (BMI).

Conditions

Interventions

BIOLOGICAL

VK2735

Administered SC

BIOLOGICAL

Placebo

Administered SC

DRUG

VK2735 Placebo

Administered orally

DRUG

VK2735 Drug

Administered orally

Sponsors & Collaborators

  • Viking Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Marianne Mancini · Viking Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-14
Primary Completion
2024-11-04
Completion
2024-12-03

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05203237 on ClinicalTrials.gov